Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 15;36(4):487-499.
doi: 10.1097/QAD.0000000000003080.

Distinct antibody profiles in HLA-B∗57+, HLA-B∗57- HIV controllers and chronic progressors

Jéromine Klingler  1 , Nicodème Paul  1 , Géraldine Laumond  1 , Sylvie Schmidt  1 , Luzia M Mayr  1 , Thomas Decoville  1   2 , Olivier Lambotte  3   4   5   6 , Brigitte Autran  7   8 , Seiamak Bahram  1 , Christiane Moog  1   2 ; and for ANRS CO21 Cohort
Affiliations

Distinct antibody profiles in HLA-B∗57+, HLA-B∗57- HIV controllers and chronic progressors

Jéromine Klingler et al. AIDS. .

Abstract

Objective: Spontaneous control of HIV replication without treatment in HIV-1 controllers (HICs) was associated with the development of an efficient T-cell response. In addition, increasing data suggest that the humoral response participates in viral clearance.

Design: In-depth characterization of Ab response in HICs may help to define new parameters associated with this control.

Methods: We assessed the levels of total and HIV-specific IgA and IgG subtypes induction and their functional potencies - that is, neutralization, phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), according to the individual's major histocompatibility complex class I (HLA)-B∗57 status, and compared it with nontreated chronic progressors.

Results: We found that despite an undetectable viral load, HICs displayed HIV-specific IgG levels similar to those of chronic progressors. Interestingly, our compelling multifunctional analysis demonstrates that the functional Ab profile, by itself, allowed to discriminate HLA-B∗57+ HICs from HLA-B∗57- HICs and chronic progressors.

Conclusion: These results show that HICs display a particular HIV-specific antibody (Ab) profile that may participate in HIV control and emphasize the relevance of multifunctional Ab response analysis in future Ab-driven vaccine studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Similar levels of anti-HIV Igs are induced in HICs and CPs.
Fig. 2
Fig. 2
Neutralizing activities against tier-2 strains are detected in HICs.
Fig. 3
Fig. 3
HICs have stronger ADCC activities than CPs.
Fig. 4
Fig. 4
Correlation between HIV-specific Ab isotypes and functional activities in B∗57+ HICs.
Fig. 5
Fig. 5
Partial least-squares discriminant analysis (PLS-DA) between a) HICs and CPs and b) B∗57+ and B∗57− HICs.
See this image and copyright information in PMC

References

    1. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. . HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053–1056. - PubMed
    1. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS Lond Engl 2009; 23:1163–1169. - PubMed
    1. Sáez-Cirión A, Pancino G. HIV controllers: a genetically determined or inducible phenotype?. Immunol Rev 2013; 254:281–294. - PubMed
    1. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. . HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 2006; 107:4781–4789. - PMC - PubMed
    1. Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. . HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007; 104:6776–6781. - PMC - PubMed

Publication types